Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 3,917,299 | $22,563,642 | 3.08% | |
| 2. | Citadel Investment Group Ken Griffin | 1,283,166 | $7,391,037 | +4% | 0% |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,034,459 | $5,958,484 | 0.15% | |
| 4. | AQR Capital Management Cliff Asness | 480,249 | $2,766,234 | +258% | 0% |
| 5. | EcoR1 Capital Oleg Nodelman | 396,194 | $2,282,077 | 0.11% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.40 | 3,000 | $43,200.00 | 108,484 | 2025-12-11 | Filing | |
| $14.49 | 7,000 | $101,395.00 | 1,551,613 | 2025-12-11 | Filing | |
| $9.94 | 3,500 | $34,804.70 | 1,543,384 | 2025-09-15 | Filing | |
| $9.51 | 6,500 | $61,818.90 | 1,539,884 | 2025-09-15 | Filing | |
| $8.50 | 5,000 | $42,515.50 | 1,533,384 | 2025-09-12 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 562,877 | $3,242,172 | 0% | |
| 2. | 187,045 | $1,077,378 | 0% | |
| 3. | 149,844 | $863,529 | 0% | |
| 4. | 116,582 | $671,512 | 0% | |
| 5. | 79,284 | $456,676 | 0% |